Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 8Cytokine Release Syndrome 3Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Schwannomatosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neurilemmoma 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoma, Non-Hodgkin 1Lymphoma 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Chronic Pain 1Carcinoma, Renal Cell 1Advanced Malignant Solid Neoplasm 1

Interventions

aldesleukin 22Sunitinib 21Bevacizumab 16Interleukin-2 14Everolimus 14Interferon-alpha 13Gemcitabine 13Cyclophosphamide 13fludarabine phosphate 11Peripheral Blood Stem Cell Transplantation 9Sorafenib 8Filgrastim 8Axitinib 8Nivolumab 7pembrolizumab 6Ipilimumab 6Doxorubicin 6Carboplatin 6sargramostim 5cabozantinib 5Capecitabine 5Thalidomide 4Tacrolimus 4Radiotherapy 4Radiosurgery 4Neoadjuvant Therapy 4Mycophenolic Acid 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4Chemotherapy, Adjuvant 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Kidney Neoplasms × siltuximab × Clear all
NCT00311545 2013-02-20

S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer

SWOG Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡